Furthermore, regorafenib, sorafenib, apatinib, and cabozantinib target multiple receptor tyrosine kinases, including VEGFRs and RET, which are considered key targets in osteosarcoma treatment and have shown clinical benefit in phase II trials [199]. Here, NTRK1 is linked to osteosarcoma.